Radiopharmaceutical firm Clarity Pharmaceuticals said that its copper-64 SAR-Bombesin (SAR-BBN) agent has been used in the first patient of its Copper-64 Bombesin in Breast Cancer Trial (C-BOBCAT).
C-BOBCAT is the first in-human clinical trial investigating the use of the radiopharmaceutical in patients with hormone-receptor-positive/HER2-negative metastatic breast
cancer, according to the company. The trial is being led by Dr. Louise Emmett of St. Vincent's Hospital in Sydney, Australia.
"We hope that SAR-BBN will allow for [PET] imaging and localization of metastatic breast cancer lesions that express [gastrin-releasing peptide receptor (GRPr)], and we look forward to utilizing that data to progress SAR-BBN into other diagnostic and therapeutic trials in a range of cancers that express GRPr with our ultimate goal of better treating children and adults with cancer," said Clarity CEO Alan Taylor, PhD, in a statement.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
